Forget Nvidia—Wall Street Sees S&P 500 at 8,900, Putting These ETFs in Play
Wall Street sees the S&P 500 climbing to 8,900. Discover which sector ETFs could benefit as investors look beyond Big Tech and the AI trade.
Stocks · News reference
Dan Loeb’s Third Point acquired approximately 85,000 Bausch + Lomb shares worth about $1.4 million as of June 30, according to the filing.
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Wall Street sees the S&P 500 climbing to 8,900. Discover which sector ETFs could benefit as investors look beyond Big Tech and the AI trade.
Four sectors are higher and seven are lower in Monday’s regular session, with defensive sectors holding the top three positions. The leaders are clustered rather than widely separated, with the top three staying within a narrow range of one another.
XBI and IBB lagged SPY and QQQ as two FDA decisions and fresh Alzheimer's and obesity-drug data put biotech ETFs in focus.
Six sectors are higher and five are lower in Friday's regular session, with the top three split across defensive, growth and cyclical groups. Consumer Staples sits well clear of the rest, separated by a margin several times wider than any other gap in the table.
As 2026 winds down, the article analyzes four key sector ETFs heading into 2027. Technology stocks have pulled back 14% from October highs after AI companies missed earnings, but the sector remains reasonably valued. Financial stocks are mixed, with insurance outperforming while banks struggle amid tepid loan demand. Energy stocks surged 40% YTD on oil prices but face headwinds as crude may have peaked around $90/barrel. Healthcare stocks are up 21% but appear slightly overvalued at current levels.
As tech stocks struggle post-election, investors are rotating into defensive sectors like healthcare. The State Street Healthcare Select Sector SPDR ETF (XLV) has gained 23% in 2026, outperforming the S&P 500's 11% return. Healthcare's inelastic demand makes it attractive during market volatility, though investors should consider dollar-cost averaging given the recent run-up.